PBM
CLDX icon

Propel Bio Management’s Celldex Therapeutics CLDX Stock Holding History

Propel Bio Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.86M Sell
103,695
-27,669
-21% -$894K 2.02% 17
2026
Q1 		$4.14M Sell
131,364
-22,936
-15% -$625K 2.61% 10
2025
Q4 		$4.19M Sell
154,300
-700
-0.5% -$18.4K 3.58% 11
2025
Q3 		$4.01M Buy
+155,000
New +$3.59M 4.01% 9

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Propel Bio Management's CLDX Position: Q2 2026 in Review

Propel Bio Management reduced its Celldex Therapeutics (CLDX) stake by 21% in Q2 2026, selling an estimated $894K and leaving 103,695 shares worth $3.86M. The position accounts for 2.02% of the portfolio, ranked #17.

Propel Bio Management first reported a position in CLDX in Q3 2025 and has held it in 4 quarters since. The position peaked at $4.19M in Q4 2025. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Propel Bio Management held 103,695 shares of Celldex Therapeutics worth $3.86M as of Q2 2026.
  • Propel Bio Management sold 27,669 Celldex Therapeutics shares in Q2 2026, an estimated $894K.
  • Celldex Therapeutics made up 2.02% of Propel Bio Management's portfolio in Q2 2026, its #17 holding.
  • Propel Bio Management first reported a position in Celldex Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Propel Bio Management's Celldex Therapeutics position peaked at $4.19M in Q4 2025.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Propel Bio Management's 13F filing for Q2 2026, filed 13 Aug 2026.